This study was designed to determine the safety of a nonmyeloablative regimen in patients with primary immunodeficiency disorders (PID) who had infections, organ dysfunction or other risk factors that precluded conventional hematopoietic cell (HC) transplant. Fourteen patients received HLA-matched related (n ¼ 6) or unrelated (n ¼ 8) HC grafts from marrow (n ¼ 8), peripheral blood mononuclear cells (n ¼ 5) or umbilical cord blood (n ¼ 1), either without conditioning (n ¼ 1), or after 200 cGy total body irradiation alone (n ¼ 3) or with 90 mg/m 2 fludarabine (n ¼ 10). All patients were given postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Mixed (n ¼ 5) or full (n ¼ 8) donor chimerism was established in 13 patients, and one patient rejected the graft. Eight patients developed acute grade III (n ¼ 1) and/or extensive chronic GVHD (n ¼ 8). With a median follow-up of 4.9 (range, 0.7-8.1) years, the 3-year overall survival, event-free survival and transplant-related mortality were 62, 62 and 23%, respectively. Correction of immune dysfunction was documented in 8 of 10 patients with stable donor engraftment. These preliminary results indicated that this approach was associated with stable donor engraftment and a low incidence of early mortality and, thus, can be considered for certain high-risk patients with PID. However, there was a risk of GVHD, which is an undesirable outcome for this group of patients.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) offers curative therapy for most patients with primary immunodeficiency disorders (PID). Successful HCT requires overcoming the bi-directional immunologic barrier composed of host-versus-graft (HVG) and graft-versus-host reactions. To accomplish this, conventional transplant regimens have employed intensive cytotoxic conditioning phases to eliminate HVG reactions, followed by the hematopoietic cell graft used both to rescue the patient from lethal myeloablation and to correct the immunodeficiency disorder. However, intensive cytotoxic conditioning regimens cause profound pancytopenia and increase the risk for severe organ toxicity. In addition, children treated with myeloablative regimens often suffer late effects such as infertility, hormonal dysfunction, growth failure and secondary malignancies. [1] [2] [3] [4] Certain factors, including older age and coexisting chronic infections or organ dysfunction, confer greater risks for toxicity or death following myeloablative conditioning regimens.
In 1997, a novel approach to overcome the bi-directional allogeneic graft barriers was reported in a canine model, which combined a nonmyeloablative conditioning regimen using low-dose total body irradiation (TBI, 200 cGy) with post-grafting immunosuppression consisting of mycophenolate mofetil (MMF) and cyclosporine (CSP). 5 The study results showed that potent immunosuppression given after marrow grafting in a major histocompatibility identical model could facilitate the development of bi-directional immunologic tolerance, prevent graft rejection and control GVHD. Subsequently, this regimen with or without fludarabine (90 mg/m 2 ) was studied as a means to establish donor engraftment in older human patients and those with comorbidities for treatment of hematologic malignancies. Early (day 100) mortality rates ranged from 4.5 to 11% depending upon donor type and extent of co-morbidities. [6] [7] [8] We hypothesized that a similar approach could be effective for treatment of PID through the establishment of stable mixed or full donor chimerism. Supportive evidence that mixed chimerism could ameliorate certain immune deficiency states has been reported in retrospective studies of patients primarily given myeloablative conditioning. 9, 10 The primary objectives of the current study were, first, to determine the safety of intensive post-transplant immune suppression after nonmyeloablative conditioning in patients with life-threatening co-morbidities and second, to test whether donor engraftment could be established in a variety of PID. A secondary objective was to determine whether mixed chimerism could improve the immunologic deficiencies in various disorders. (Table 1) . Results were analyzed as of 17 January, 2006. Patients were eligible for the study if all of the following criteria were present: (1) a PID treatable with HCT; (2) factor(s) that would increase the risk of early transplant-related mortality (TRM, death before day 100) following conventional HCT; and (3) identification of a related or unrelated donor matched for HLA-A, -B, -C, -DRB1 and -DQB1 alleles. Factors considered to increase the risk of mortality included: (1) infection-defined as fungal or viral infections involving one or more organs present at time of transplant or a life-threatening opportunistic infection diagnosed within 3 months of HCT; (2) organ dysfunction-defined as any of the following: liver dysfunction (transaminase 43 times the upper limit of normal), renal dysfunction (biopsy-proven renal disease or glomerular filtration rate o50%), cardiac dysfunction (cardiac ejection fraction o40%), or pulmonary dysfunction (diffusing capacity of the lung for carbon monoxide of o60%); (3) older age (45 years)-applicable only in cases for which previous studies have documented age to be associated with higher risk of TRM; 10,11 (4) unrelated donor (URD)-applicable only in disorders for which previous studies have documented disease-free survival of o50% or if the reported experience has not been sufficient to justify a conventional URD HCT. 10 Excluded from this analysis were patients with severe combined immunodeficiency disorder who received grafts from HLA-matched related donors (n ¼ 1). Patients and/or their parents signed forms approved by the FHCRC Institutional Review Boards documenting informed consent to participate in the clinical trials.
Methods

Patients
Histocompatibility
Methods used for histocompatibility testing have been reported previously.
12,13 DRB1 and DQB1 alleles were determined by hybridization of sequence-specific oligonucleotide probes.
14 Direct automated fluorescent methods were used to identify HLA-A, -B and -C alleles. 15 Related and unrelated donors were matched for alleles at HLA-A, -B, -C, -DRB1 and -DQB1.
Preparative regimen
Post grafting immunosuppression with high-dose CSP and MMF was given after a nonmyeloablative conditioning regimen. Since CSP and MMF could exacerbate infections present pretransplant, the regimen was intensified by stages in patients as follows: patients received no conditioning (n ¼ 1), 200 cGy TBI (7 cGy/min; day 0, n ¼ 3) or 200 cGy TBI plus fludarabine (30 mg/m 2 /day; days À4 to À2; n ¼ 10). Patients received unmanipulated bone marrow (n ¼ 8), granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (G-PBMC, n ¼ 5) or umbilical cord blood (n ¼ 1) collected according to established methods and infused through a central venous catheter on day 0. 16, 17 The median total nucleated, CD34, and CD3 cell doses were 6.5 (range, 1. 
Post-grafting immunosuppression
All patients received CSP and MMF for postgrafting immunosuppression. CSP was initiated on day À3 at doses of 2 mg/kg intravenously every 8 h for children less than 6 years of age or 1.5 mg/kg intravenously every 12 h for older children. The dose of CSP was adjusted to achieve serum trough levels between 400 and 600 ng/ml through day 28 after HCT; after stable therapeutic levels were achieved, the intravenous form was converted into the oral form (Neoral). The duration of CSP prophylaxis after transplant was extended to 180 days with the aims of reducing both the incidence and severity of GVHD. 18 MMF was administered to the first six patients at a dose of 15 mg/kg orally or intravenously every 12 h, commencing 4 h after the marrow infusion and continuing until day þ 27 after HCT. Subsequently, MMF was given every 8 h after pharmacokinetic studies in adult patients established the halflife. 7, 19, 20 Patients received MMF from day 0 to day 40 followed by a taper of 11% per week if there was no evidence of GVHD. If patients developed GVHD, treatment with CSP and/or MMF was extended.
GVHD grading and treatment
Diagnosis and clinical grading of acute and chronic GVHD were performed according to established criteria 21, 22 and treated as described previously. 23, 24 Patients were not considered evaluable for acute GVHD if they died before engraftment or for chronic GVHD if they died before day 80.
Prophylaxis against infection
Measures to prevent infection included intravenous immunoglobulin, prophylactic fluconazole, trimethoprimsulfamethoxazole or other prophylaxis for Pneumocystis carinii pneumonia (PCP), acyclovir if indicated for prevention of herpes simplex virus reactivation, and pre-emptive ganciclovir or foscarnet if cytomegalovirus (CMV) antigen was detected. 25, 26 Reactivation of CMV and Epstein-Barr virus (EBV) was detected using PCR amplification of nucleic acids from serum samples, as described pre- Table 1 Characteristics and outcomes of 14 patients who received nonmyeloablative conditioning followed by allogeneic grafts for high-risk PID viously. 27, 28 Patients with chronic GVHD were given prophylaxis for PCP and pneumococcal infections through the duration of immunosuppressive therapy.
Flow cytometric analysis, cell sorting and chimerism analyses Procedures for immunophenotype analyses and sorting of cell subsets by flow cytometry have been described previously. 29, 30 Donor chimerism levels were assessed in sorted CD33, CD3, CD4, CD8, CD19 and CD56 cell subsets by FISH to detect X and Y chromosomes for recipients of sex-mismatched grafts, or by PCR-based analyses of polymorphic microsatellite regions for recipients of sex-matched grafts, using methods described previously. [31] [32] [33] [34] Disease response Recovery of T-and B-cell numbers was evaluated by flow cytometry using specific monoclonal antibodies to CD3, CD4, CD8 and CD19. Lymphocyte function was assessed by measuring lymphocyte proliferation to mitogen (PHA), anti-CD3 antibody and antigens (tetanus toxoid and candida). Proliferation was measured by [H 3 ]thymidine incorporation according to standard methods. 35 In vivo antibody responses were evaluated using immunization with the T cell-dependent neoantigen, bacteriophage FX174, as described previously. 36, 37 Surface staining and flow cytometry for functional CD40 ligand expression were performed on stimulated lymphocytes as described previously. 38 Neutrophil oxidative burst was determined by flow cytometry using dihydrorhodamine fluorescence as described. 39 Definition of study end points The primary end points of the study were safety, TRM and donor engraftment. TRM was defined as death at any time from causes other than the underlying disease. Early TRM was defined as death before day 100. Death due to infection was scored as TRM, including patients who had preexisting infections. Event-free survival was defined as time to death or rejection, whichever came first. Adverse events were graded by the common toxicity criteria version 3. Donor engraftment was defined as achievement of at least 5% peripheral blood CD3 cells of donor origin. Mixed chimerism was defined as 5-94% CD3 cells of donor origin, and full chimerism was defined as X95% CD3 cells of donor origin. Graft failure was defined by failure to achieve at least 5% CD3 cells of donor origin and absolute neutrophil counts 4500/ml for 3 consecutive days and/or subsequent loss of donor engraftment (o5% donor CD3).
Statistical methods TRM and incidence of GVHD were calculated using a cumulative incidence estimate, treating rejection and malignancy as competing risk events for TRM and second transplant, death, DLI and malignancy as competing risk events for GVHD. 40 Survival and event-free survival curves were calculated using the Kaplan and Meier method. 41 Time to death (for overall survival) or rejection (for eventfree survival) was censored at the last contact date for each patient. Plots of individual patients' hematologic parameter trajectories included median curves smoothed with cubic spline functions.
Results
Hematologic recovery
For those patients who received conditioning (n ¼ 13), absolute neutrophil counts (ANC) declined to a median value of 221 (range, 24-930) cells/ml within the first 30 days, with the nadir occurring at a median of 12 (range, 0-30) days after HCT (Figure 1a) . The median durations of ANC o500 cells/ml and o1000 cells/ml were 15 (range, 5-23) and 20 (range, 5-35) days, respectively, after HCT. Four patients received G-CSF for treatment of neutropenia (ANC o500 cells/ml). The median duration of platelet counts o20 000 ml was 12 (range, 6-16) days (Figure 1b) . The median number of platelet and packed red blood cell transfusions were 0 (range 0-64) and 4 (range 1-93), respectively.
Donor chimerism
The percent of donor cells among CD33, CD3, CD4, CD8, CD19 and CD56 subsets are provided at days 28, 90, 365 and at last follow-up (Table 2) . Full donor CD3-cell chimerism was documented at 7.3, 2.9 and 0.2 years after HCT in the three patients with SCID. Donor CD19 cell chimerism was established in one of two X-SCID patients with sufficient follow-up (patients no. 1 and no. 2), and in a RAG2 SCID patient after a planned stem cell boost. Among the 11 patients with PID other than SCID, full donor and mixed donor CD3 chimerism was established in five and five patients, respectively. One patient (no. 5) rejected the graft, and had uneventful recovery of autologous hematopoiesis.
Transplant-related toxicity and mortality Early TRM (oday 100) was 0% and the 3-year TRM was 23%. One patient died before day 180 of disseminated CMV disease. This patient had ganciclovir-resistant CMV pneumonitis and viremia, with 240 000 copies of CMV by PCR, at time of HCT. Three patients had grade IV nonhematologic organ toxicities before day 100, which included hyperbilirubinemia (not caused by sinusoidal obstructive syndrome), hypotension, hypoxia, hyponatremia/adrenal insufficiency and renal failure. There were no grade V toxicities. Bacterial infections were diagnosed in eight patients, and none of the patients developed a fungal infection. Among the nine patients at risk for CMV reactivation, two reactivated and were treated with preemptive ganciclovir until day 100.
GVHD
Of the 14 patients, 10 developed acute grade II GVHD (6/8 recipients of marrow and 4/5 recipients of G-PBMC), and 1 developed acute grade III GVHD (Table 1) . No patient developed acute grade IV GVHD. The cumulative incidences of acute GVHD grade II and III were 71 and 7%, respectively. The median onset of grade II-III GVHD was 18 (range, 7-71) days after HCT. Extensive chronic GVHD developed in eight patients (2/6 recipients of related grafts and 6/8 recipients of unrelated grafts; 4/5 recipients of G-PBMC grafts and 4/8 recipients of marrow grafts). The 1-year cumulative incidence of extensive chronic GVHD was 47%. Complications from chronic GVHD were responsible for the death of one (7%) patient. At time of last follow-up, nine patients were alive, and all had a Lansky/Karnofsky performance score of 100. Of the nine patients, six do not require treatment for GVHD, while three patients continue to receive immunosuppression at 0.7, 6.2 and 7.5 years after HCT.
Second HCT or donor lymphocyte infusion
Three patients met criteria for a second donor cell infusion. Patient no. 3 established full donor CD3 cells, but lost the granulocyte graft, and was given stored peripheral blood stem cells from the original donor following no conditioning, which successfully established full donor CD33 chimerism. Patient no. 8 also established full donor CD3 chimerism, associated with resolution of disseminated infections, but thrombocytopenia persisted. A second marrow graft from the original donor was given after conditioning with fludarabine (total dose 120 mg/m 2 ) and oral busulfan (BU, total dose 16 mg/kg), which resulted in full chimerism of the CD33 compartment. He survives 44.9 years with 100% donor chimerism of CD3 and CD33 cells and a normal platelet count. Patient no. 12 had persistent low level donor CD4 and CD8 chimerism, which did not improve substantially after DLI was given 5 months after HCT. This patient subsequently received a second transplant following a reduced intensity regimen. 42 One patient (no. 5) was given a second transplant for treatment of graft rejection, using the same donor after a myelo- Table 2 Percent donor chimerism levels of sorted peripheral blood cell subsets at days +28, +90, +365, and last follow-up for 14 ablative regimen (oral BU (total dose 16 mg/kg), cyclophosphamide (CY, total dose 120 mg/kg) and anti-thymocyte globulin (ATG, total dose 90 mg/kg)) which resulted in full donor chimerism, however, the patient died from toxicity related in part to her pretransplant pneumonitis.
Disease responses
Ten of the 14 patients were evaluated for disease response. The four patients who received a stem cell boost, second HCT or DLI (nos. 3, 5, 8, and 12) were not included in this evaluation. Correction of or improvement in the PID was documented in 8 of the 10 patients (Table 3 ). The two patients with X-SCID (nos. 1, and 2), had significant improvement in T-cell numbers and function (Table 3) . Antibody response and antibody class switching normalized in patient no. 2 who had full donor chimerism of B cells. Patient no. 1 has not yet been immunized with bacteriophage FX174 to assess B-cell immunocompetence. Eight patients with PID other than SCID were evaluated clinically and with disease-specific assays to determine disease response. Lymphocyte numbers and function were found to be normal or near normal in the patient with CVID (no. 4) and in 1 of the 2 patients (no. 6 and no. 7) transplanted for T-cell defects, as shown in Table 3 . The patient with common variable immunodeficiency (no. 4) was immunized with bacteriophage FX174 3 years after HCT and demonstrated a normal primary antibody, however, the patient did not follow-up and the full immunization series was not completed. Clinically at the time of HCT he had persistent fevers, severe failure to thrive weighing 40 kg and suffered from disseminated mycobacterium avium complex (MAC), which resolved following HCT and currently he remains well 8.1 years after HCT. Patient no. 6 also developed a near-normal primary and secondary antibody response to immunization with bacteriophage FX174, compared to the pretransplant evaluation (data not shown). Clinically, he remains without significant infectious complications 5.5 years after HCT. Patient no. 7 was evaluated at 1 year after HCT while being treated with immune suppressants for GVHD, which may have contributed to the delay in immune reconstitution. Both patients with Wiskott-Aldrich Syndrome (no. 8 and no. 9) developed normal T cell function after HCT. Table 3 excludes the data for patient no. 8, since the last evaluation was performed after the second graft given to correct the platelet defect. The platelet count in patient no. 9 normalized after HCT, which correlated with full donor chimerism of CD33 cells. Among the two patients with X-linked hyper IgM syndrome (CD40 ligand deficiency (CD40LD)), one (no. 11) was found to have a marked increase in functional CD40 ligand expression on activated T cells (data not shown). Immunization with bacteriophage FX174 showed near-normal primary and secondary antibody responses and improved IgM to IgG class switching (data not shown). This patient has remained free of infections 44 years after HCT. The other patient (no. 10) has not been evaluated for immune reconstitution; however he has been treated intermittently for CMV reactivation, suggesting poor T-cell immunity. His donor was subsequently found to be a carrier of the CD40 ligand mutation, which in addition to the low-level chimerism likely explains the persistent T-cell defect. The patient with chronic granulomatous disease (CGD) showed normal neutrophil oxidative burst (patient stimulation index (SI) ¼ 128.8, control SI ¼ 152.7) following HCT compared to before HCT (patient SI 1.2, control SI 152.9) (data not shown). The patient with cartilage hair hypoplasia (no. 14) developed a marked improvement in T-cell function following HCT. (Table 3 ) Clinically this patient, who was severely neutropenic and dependent on G-CSF before HCT, remains healthy with a normal white blood count 9 months after HCT.
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(n ¼ 1), cardiac arrest of unknown etiology (n ¼ 1) and transplant-related toxicities following second myeloablative HCT (n ¼ 1) ( Table 1) .
Discussion
While HCT is effective in the treatment of a variety of PID, it is reasonably common for these patients to have infections or organ dysfunction as a consequence of their disease, which confer higher risk for mortality after HCT. Filipovich et al. showed that patients could be defined as 'high-risk' if they developed life-threatening co-morbidities within 3 months of unrelated donor HCT, with an overall survival of 20% compared to 80% survival after HCT for the healthy, average risk patients. 11, 43 Our own unpublished data shows 50% mortality by day þ 100 for high-risk patients with PID, compared to 11% for those without risk factors. Older age has been associated with higher TRM rates following HCT for PID, which may be a consequence of delaying HCT until medically necessary. The risk of mortality also has been correlated with the subtype of PID, for example CGD, CD40LD and TCD consistently have lower survival rates compared to patients given HCT for treatment of other diagnoses. 10, 44 Finally, several studies have reported rates of TRM exceeding 30% following unrelated grafts. 10, 45 Accordingly, for the subset of highrisk PID patients, the development of a less toxic HCT regimen would provide considerable benefit and perhaps encourage HCT at an earlier age. This study found that the combination of MMF and CSP used as intensive immune suppression following a nonmyeloablative conditioning regimen reduced the incidence of early mortality for patients who would be considered a high risk for TRM, even those with life-threatening infections at the time of HCT.
The aim of this pilot study was to determine the safety of intensive post-grafting immunosuppression in high-risk patients; consequently, the study is limited with respect to analysis for efficacy. Nonetheless, disease responses were observed in patients with partial as well as full donor chimerism. There are several points regarding the efficacy of establishing donor chimerism and disease responses worth considering. First, the level of donor engraftment needed for disease response is disease-specific. Immunodeficiency disorders, in general, are predicted to be correctable with lower level donor chimerism based upon observations of female carriers of X-linked immunodeficiencies with random X-chromosome inactivation who are clinically normal. Moreover, disease responses have been reported in patients with mixed chimerism following conventional HCT. 10 Accordingly, in this study improvement of the immune deficit was observed in most of the patients with mixed chimerism. However, certain PID may require higher level donor chimerism for correction, illustrated by patient 10, who did not have clinical improvement in immune function despite stable chimerism of 10-15% (although the donor cells were from a female carrier, which may in part have contributed to the persistent immune deficiency). Second, disease response will depend upon engraftment of the appropriate cell lineages. This is best illustrated in the patients with Wiskott-Aldrich syndrome, in which donor origin of lymphoid lineage cells corrected the immune defect, whereas thrombocytopenia was corrected only if myeloid lineage cells were of donor origin. Finally, establishment of donor T-cell chimerism may be a bridge to a second transplant. Patients with life-threatening infections could safely be given HCT using this nonmyeloablative regimen to establish donor T-cell chimerism, which established tolerance and enabled recovery from infection. Subsequently, a second infusion of cells could be given with less risk to convert to full chimerism.
It may be argued that study of this nonmyeloablative regimen in a diverse group of patients will make it difficult to come to conclusions regarding its usefulness. However, these disorders are rare and no single center could accrue enough patients for analysis of efficacy in a single disorder. Moreover, there have been several other reports of reduced toxicity regimens that have been studied in small numbers of patients with PID. Amrolia and colleagues studied fludarabine (150 mg/m 2 ), melphalan (140 mg/m 2 ) and antilymphocyte globulin (12.5 mg/kg) as conditioning for marrow grafts in eight patients with various PID. 46 Other than myelosuppression and hepatotoxicity, no life-threatening toxicities were observed. Seven of the eight patients were reported to survive 8-17 months after HCT, with high-level donor chimerism in six and mixed donor-host chimerism in two patients. Horwitz and colleagues 47 were able to study 10 patients with CGD who were conditioned with CY (120 mg/kg), fludarabine (125 mg/m 2 ) and ATG (160 mg/kg), followed by transplant of HLA-matched CD34 þ -selected PBMC. Delayed DLI was given to increase the level of donor chimerism. Donor chimerism was established in 9 of 10 patients, and GHVD developed in three patients after DLI. Seven patients were reported to have survived from 16 to 26 months, two patients died of transplant-related complications and one patient who rejected the graft died after a second HCT. More recently, Rao et al. 48 reported the outcomes of 33 patients with PID (SCID (n ¼ 6) and non-SCID (n ¼ 27)) who received unmodified unrelated donor marrow grafts following reduced intensity conditioning consisting of fludarabine (150 mg/m (0.2 mg/kg, days À8 to À4, n ¼ 14) or ATG (2.5 mg/kg, day -2 to þ 2, n ¼ 19). All patients had primary engraftment, and at time of last follow-up (41 year), 55% of the patients had 100% donor chimerism. The incidence of acute GVHD (4grade II) was 9% and 1-year survival was 94%. While these reduced-intensity regimens show promising results, the high degree of immune suppression may not be desirable for those patients with life-threatening infections. As our study demonstrated, a minimal toxicity conditioning regimen combined with intensive post-grafting immune suppression facilitated donor engraftment with low risk of mortality from opportunistic infections. As described previously in the setting of minimal conditioning, alloreactivity of the donor graft plays an important role in establishing donor hematopoiesis.
5-8 Not unexpectedly we observed GVHD, which in one case contributed to TRM. We believe that, unlike patients with hematologic malignancies, who benefit from the graft-vsleukemia effect of donor cells, there is no clinical benefit from GVHD in patients with PID. In retrospect, several factors contributed to the high incidence of GVHD in this study. First, we found that the grafts contained large doses of both CD34 and CD3. Kahl et al. 49 recently published a study in 81 patients with severe aplastic anemia and found higher numbers of nucleated marrow cell doses (42.4-3.2 Â 10 8 cells/kg) were associated with an increased risk of developing extensive chronic GVHD (hazard ratio 3.8). Second, higher rates of chronic GVHD were seen among recipients of G-PBMC grafts compared to marrow. This finding is consistent with studies comparing G-PBMC to marrow among recipients of both related and unrelated donor grafts. 50, 51 We initiated the study with a preference for G-PBMC as the stem cell source because canine studies and clinical trials in adult patients with malignancies showed a higher risk of graft rejection following marrow grafts. 7, 8 However, in this study we could not appreciate a difference in graft rejection according to stem cell source, although this could be explained by the relatively high cell dose of the marrow products. Finally, unrelated donor grafts, which were given to over half of the patients in this study, have been associated with higher incidences of acute grade II-IV and chronic GVHD, compared to related donor grafts in patients with hematologic malignancies conditioned with this nontoxic-conditioning regimen. 52 It should be noted, however, that the quality of life scores were high in our patients, despite the presence of chronic GVHD in many.
This study translated treatment with a minimal toxicity nonmyeloablative HCT, first developed in the dog model and then studied extensively in adult patients with malignant disorders, to high-risk PID with the aim of reducing early TRM. As a first step toward improving survival of high-risk patients, we showed that early TRM could be reduced and immune function could be improved. Current studies are aimed at reducing the incidence of chronic GVHD, the most important obstacle to successful application of this regimen. Nonetheless, our study adds to the emerging field of reduced intensity or nonmyeloablative HCT for treatment of PID, which indicate that the toxic effects of conventional regimens can be reduced without compromising donor engraftment. A minimal-toxicity HCT is a viable treatment approach and may provide the only acceptable transplant option for high-risk patients with life threatening co-morbidities.
